AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Want to cut your energy bills? Here’s how five experts are doing it 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Elon Musk's Terafab Foundry Courts Top Chipmaking Giants for AI Self-Sufficiency Push 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
CSN's Cement Unit Sale Could Exceed $2 Billion as Global Giants Circle 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Federal Agencies Secretly Test Anthropic's AI Despite Trump Administration Ban 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
EMERYVILLE, Calif., May 31, 2017 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today announced that Michael P. Smith, Executive Vice President, Chief Financial Officer & Treasurer and Secretary, will present a corporate overview at the Jefferies 2017 Global Healthcare Conference, taking place on June 6-9, 2017, in New York, NY.
Zogenix Presentation Details
| Date: | Wednesday, June 7, 2017 |
| Time: | 2:00 pm Eastern Time / 11:00 am Pacific Time |
The presentation will be webcast live and archived for 30 days on Zogenix's Investor Relations website at ir.zogenix.com.
About Zogenix
Zogenix, Inc. (Nasdaq:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT: Investors: Andrew McDonald Founding Partner, LifeSci Advisors LLC 646-597-6987 | [email protected]
